Conditions: Head and Neck Squamous Cell Carcinoma; Margin Assessment
Intervention: Drug: Cetuximab-IRDye800CW
Sponsors: University Medical Center Groningen; UMC Utrecht; Erasmus Medical Center, Rotterdam
Not yet recruiting - verified April 2017
from #ORL via a.lsfakia on Inoreader http://ift.tt/2pOLCQI
via IFTTT
http://ift.tt/2pohpGw
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
The aromatic amino acid hydroxylase (AAAH) enzyme family includes phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH) and the tryptop...
-
Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma Recent Results Cancer Res. Authors: Raue F, Frank-Raue K Abstrac...
-
ORAL LICHEN PLANUS: AN UPDATE : 2016-11-07T08-18-18Z Source: International Journal of Current Research and Review Md. Asad Iqubal, Mobe...
-
Abstract Hepatocytes derived from human induced pluripotent stem cells (iPSCs) hold great promise as an in vitro liver model by virtue of t...
-
EDITORIAL Pediatric retina: A challenging yet fascinating field p. 179 Wei-Chi Wu DOI :10.4103/tjo.tjo_123_18 [HTML Full text] [PDF] ...
-
Degradation of acetalated dextran can be broadly tuned based on cyclic acetal coverage and molecular weight. Int J Pharm. 2016 Aug 16;...
-
Abstract Purpose The present study aimed to determine the level of physical activity (PA) among prostate cancer (PCa) patients across tr...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου